http://www.novartis.com 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml 2010-03-18T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1395085.shtml 2010-02-22T07:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386845.shtml 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml 2009-12-21T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1365351.shtml 2009-12-18T15:24:29 CET http://www.novartis.com/newsroom/media-releases/en/2009/1365021.shtml 2009-11-24T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1356789.shtml About MF59® 2009-11-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1355458.shtml About A(H1N1) 2009 Vaccine 2009-11-13T16:41:22 CET http://www.novartis.com/newsroom/media-releases/en/2009/1355007.shtml Basel, November 13, 2009 - Novartis announced today that Celtura®, the company's adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, has received approval in Switzerland from Swissmedic, the Swiss Agency for Therapeutic Products. This is the second marketing approval for the cell-culture based A(H1N1) pandemic vaccine in Europe. Celtura was approved in Germany earlier in November 2009. The company also has submitted a registration for Celtura in Japan, and will seek approval in a number of other countries. 2009-11-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1352736.shtml About Novartis 2009-10-29T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1351038.shtml Basel, October 29, 2009 - Novartis confirmed today that it has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS). 2009-10-22T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1349248.shtml Basel, October 22, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased with our strong underlying performance, led by the momentum of our Pharmaceuticals business, outpacing the competition and benefiting from innovative product growth rejuvenating the portfolio. Our investments in R&D show excellent results, with many key approvals in 2009, most notably the anti-cancer therapy Afinitor and the biotechnology medicine Ilaris. Deliveries of H1N1 pandemic flu vaccines are underway as Novartis works at full capacity to meet public health demands. The Sandoz generics business also made good progress, coupled with a turnaround in the US. We expect record full-year underlying results based on the significant progress to date in 2009. 2009-10-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1345850.shtml About seasonal influenza 2009-09-25T11:29:47 CET http://www.novartis.com/newsroom/media-releases/en/2009/1343650.shtml About MF59® 2009-09-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1339223.shtml Basel, September 3 2009 - A pilot trial of Novartis adjuvanted cell culture-based A(H1N1) vaccine[1] indicates that the swine flu vaccine elicited a strong immune response and was well tolerated. The trial was run by the UK's University of Leicester and University Hospitals of Leicester. The vaccine, to be called Celtura®, was tested with 100 healthy volunteers, aged between 18 and 50. 2009-08-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1332676.shtml Basel, August 5, 2009 - Novartis Vaccines has started shipping seasonal influenza vaccine to U.S. healthcare facilities for the 2009-2010 season. The company delivered Fluvirin® influenza virus vaccine, which has been approved by the U.S. Food and Drug Administration (FDA), to the U.S. weeks ahead of schedule in anticipation of the increased demand for seasonal influenza vaccine created by the current global (A) H1N1 influenza pandemic. 2009-07-16T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329090.shtml Basel, July 16, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of our recently launched products. Our pipeline continues to deliver a steady stream of innovative medicines. In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are advancing well in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus, with clinical trials set to begin in July. We continue to expect record underlying results in constant currencies based on innovation and productivity initiatives. 2009-07-01T02:10:21 CET http://www.novartis.com/newsroom/media-releases/en/2009/1326284.shtml Cambridge, MA, June 30, 2009 - Novartis Vaccines and Diagnostics received feedback from the US Food and Drug Administration (FDA) in the form of an initial regulatory determination on the Biologics License Application (BLA) for the investigational vaccine Menveo®. 2009-06-12T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1322241.shtml Basel, June 12 2009 - Novartis has successfully completed the production of the first batch of influenza A(H1N1) vaccine, weeks ahead of expectations. Cell-based manufacturing technology[1] allows vaccine production to be initiated once a pandemic virus strain is identified without the need to adapt the virus strain to grow in eggs, as with traditional vaccine technologies. This advance has cut weeks off the time required to begin vaccine production. This first batch of ten liters of wild type influenza A(H1N1) vaccine monobulk will be used for pre-clinical evaluation and testing and is also being considered for use in clinical trials. It demonstrates the value of the cell-based production approach, that is also being used by Novartis with reassortant influenza A(H1N1) seed. 2009-06-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1319838.shtml About NVGH 2009-05-26T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1317593.shtml About Haemophilus Influenzae Type B 2009-04-30T08:18:20 CET http://www.novartis.com/newsroom/media-releases/en/2009/1310049.shtml Basel, April 30 2009 - A study published this week in the Proceedings of the National Academy of Sciences of the United States of America shows that Aflunov®, the Novartis investigational pre-pandemic avian influenza vaccine formulated with Novartis' proprietary MF59® adjuvant, can elicit a broadly cross-reactive immune response covering all known H5N1 antigenic variants, even when that booster dose is administered six years after the initial priming dose. 2009-04-23T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329178.shtml 2009-04-02T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1303085.shtml Basel, April 2, 2009 - The European Commission has granted Marketing Authorization to Ixiaro® vaccine for the prevention of Japanese Encephalitis (JE). JE, a mosquito-borne flaviviral infection, results in 10,000-15,000 deaths annually[1],[2] and is a potentially life-threatening disease for travelers to Asia. 2009-03-30T23:27:57 CET http://www.novartis.com/newsroom/media-releases/en/2009/1301829.shtml Basel, March 30, 2009 - The United States Food and Drug Administration has approved Ixiaro® vaccine for the prevention of Japanese Encephalitis (JE). The vaccine will be marketed in the US as Ixiaro by Novartis Vaccines. JE, a mosquito-borne flaviviral infection, is a devastating disease that results in 10,000-15,000 deaths annually[1],[2] and is a potential threat for travelers to Asia. 2009-01-28T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1285325.shtml Basel, January 28, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: Thanks to successful innovation and a leading market position of our healthcare business portfolio, Novartis achieved a strong performance in 2008. Pharmaceuticals returned to dynamic growth and gained market share in the second half of the year, while Vaccines and Diagnostics continued its double-digit growth. Recently launched pharmaceutical products contributed USD 2.9 billion in sales in 2008 further rejuvenating our portfolio, and we submitted 14 major new products filings that underpin our innovation power. Organic growth was complemented by several acquisitions and strategic investments, the most important being the acquisition of a 25% share of Alcon. Novartis anticipates another year of record results in 2009, continuing on its path of sustainable growth. 2009-01-27T22:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1285136.shtml Emeryville, CA, January 27, 2009 - Chiron, a Novartis (NYSE:NVS) business, announced today that it has agreed to extend and expand its blood screening collaboration with Gen-Probe (NASDAQ: GPRO) until 2025. The companies will continue to work together to develop and commercialize molecular technologies that safeguard the world's donated blood supply. 2009-01-15T16:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1282432.shtml Basel, January 15, 2009 -- Novartis announced today that the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS, BARDA) has awarded Novartis Vaccines a contract for up to USD 486 million over eight years to support the design, construction, validation, and licensing of U.S. cell-based influenza vaccine manufacturing facilities in Holly Springs, North Carolina, to provide a pre-pandemic supply of influenza vaccine and to provide the capacity to manufacture 150 million doses of pandemic vaccine within six months of declaration of an influenza pandemic. 2008-12-29T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1279693.shtml Basel, December 29, 2008 - Novartis has strengthened its vaccines pipeline through an exclusive agreement to license AlphaVax' investigational Cytomegalovirus (CMV) vaccine program. This CMV agreement adds to Novartis' promising early stage pipeline of novel vaccines, which focuses on significant unmet needs for the prevention of fatal diseases such as meningococcal infections and other hospital and community acquired infections. These include vaccines to prevent Helicobacter pylori infections, a major cause of gastritis that can lead to gastric cancer, and a Group B Streptococcus vaccine candidate with potential to protect against 85 percent of neonatal sepsis and meningitis. 2008-10-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1260877.shtml Basel, October 20, 2008 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: Led by the enhanced performance of Pharmaceuticals in all regions as well as solid sales growth in Vaccines and Diagnostics and productivity gains in Consumer Health, we have achieved strong results in the third quarter of 2008 despite significant volatility in the global economic environment. We are rejuvenating our portfolio as recently launched pharmaceutical products provided USD 2.1 billion in sales to date in 2008 and several novel medicines have been recognized for their benefits to patients with priority review status at the FDA. Also, with a strong new leadership team, Novartis is positioning itself for continued growth and success in a demanding environment. Despite the economic uncertainty in the world markets, Novartis is on track for another year of record results in 2008, continuing to build momentum by focusing on innovation and performance. 2008-09-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1252754.shtml Basel, September 19, 2008 - A new study shows that individuals immunized six years earlier with an MF59 adjuvanted H5N3 (clade 0) vaccine mounted a protective immune response seven days after a single immunization with an H5N1 (clade 1) vaccine containing the Novartis proprietary adjuvant MF59. The immune response was broadly cross reactive and covered all H5N1 clades known to date. These data were presented at the Third European Influenza Conference in Vilamoura, Portugal. 2008-09-10T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1250239.shtml Novartis investigational MenB vaccine study details[1] 2008-08-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1241557.shtml Basel, August 7, 2008 - Novartis announced today that it started shipments of its Fluvirin® Influenza Virus Vaccine to US health care facilities and practitioners for the 2008/2009 influenza season. 2008-07-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1236488.shtml Basel, July 17, 2008 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: The growth acceleration in the second quarter of 2008 and our R&D successes, especially in Pharmaceuticals and Vaccines, demonstrate that our strategy is delivering results and that we are heading towards a promising future despite a weak economy. Speed and productivity of operations are improving and growth in most countries is dynamic. 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml 2010-04-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1405500.shtml 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml 2009-11-05T07:16:26 CET http://www.novartis.com/newsroom/media-releases/de/2009/1352781.shtml Basel, 5. November 2009 - Novartis gab heute bekannt, dass das Unternehmen in Deutschland von der zuständigen Zulassungsbehörde (Paul-Ehrlich-Institut) die Zulassung für Celtura®, seinen adjuvierten, monovalenten Influenza A(H1N1)-Impfstoff 2009 auf Zellkulturbasis, erhalten hat. Novartis wird jetzt die Zulassung in weiteren wichtigen Ländern vorantreiben 2009-10-22T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1349244.shtml Neun Monate bis 30. September 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr 2009-06-12T07:15:00 CET http://www.novartis.com/newsroom/media-releases/de/2009/1322242.shtml Basel, 12. Juni 2009 - Novartis hat die Produktion der ersten Charge eines Influenza A(H1N1)-Impfstoffes Wochen früher als erwartet abgeschlossen. Die Herstellungstechnologie auf Zellkulturbasis schafft die Voraussetzung, die Impfstoffproduktion zu starten, sobald ein pandemischer Virusstamm identifiziert ist, ohne dass dieser für die Vermehrung an Hühnereiern angepasst werden muss. Dieser Vorteil hat die erforderliche Zeit bis zur Impfstoffproduktion um Wochen verkürzt. Die erste Charge mit zehn Litern Wildtyp-Influenza A(H1N1)-Impfstoff-Monobulk wird für prä-klinische Untersuchungen und Tests genutzt und wird außerdem für klinische Studien in Betracht gezogen. Es beweist den Wert der Zellkultur-Produktion, die Novartis auch für das re-assortante Influenza A (H1N1)-Saatvirus nutzen will 2009-06-04T07:15:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1319840.shtml Basel, 4. Juni 2009 - Novartis gab bekannt, dass das Novartis Vaccines Institute for Global Health (NVGH) eine Beihilfe des Wellcome Trust erhalten hat, um einen bivalenten Impfstoff gegen das Typhusfieber zu entwickeln. Mehr als 21Millionen Menschen erkranken jährlich an Typhus. 2009-04-23T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329173.shtml 2009-01-28T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1285324.shtml Zwölf Monate 2008-10-20T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2008/1260875.shtml Neun Monate bis 30. September